Cancer Genetics is an esteemed peer-reviewed journal dedicated to advancing the field of cancer research through the lens of genetics. Published by Elsevier Science Inc and available in both print (ISSN: 2210-7762) and online (E-ISSN: 2210-7770), this journal aims to provide a platform for the dissemination of high-quality studies that unravel the genetic underpinnings of cancer. Since its inception in 2011, Cancer Genetics has become a significant resource for researchers, professionals, and students with a shared interest in understanding the intricate relationship between genetics and oncogenesis. With an impact factor that reflects its influence, the journal has maintained a Q3 ranking in Cancer Research, Genetics, and Molecular Biology as of 2023, indicating its growing importance in these fields. Additionally, the journal offers open access options to ensure that crucial findings are easily accessible to the global research community. By bridging the gap between genetics and cancer studies, Cancer Genetics plays a pivotal role in fostering innovation and collaboration among scientists and clinicians striving to improve cancer diagnosis and treatment.

Lung Cancer - Targets and Therapy, published by Dove Medical Press Ltd, serves as a pivotal Open Access journal dedicated to advancing knowledge and research in the field of oncology, specifically focusing on lung cancer. Since its inception in 2010, this journal has provided a platform for disseminating high-quality research articles, reviews, and clinical studies, thereby enhancing the understanding of lung cancer mechanisms, therapies, and clinical outcomes. Currently ranked in the Q2 quartile within the oncology category and positioned at rank #80 out of 404 in Scopus, it resides in the 80th percentile of its field, reflecting its significant impact and relevance. With a commitment to promoting innovative therapies and strategies, Lung Cancer - Targets and Therapy is an essential resource for researchers, healthcare professionals, and students eager to contribute to the evolving landscape of cancer treatment and research.

Oncology Research and Treatment, published by KARGER, is a highly regarded academic journal dedicated to advancing the field of oncology through rigorous research and clinical insights. With a history spanning from 1978 to 1997 and continuing from 2013 to 2024, this journal provides a vital platform for researchers and professionals in cancer research, hematology, and related disciplines. Though currently listed in the Q3 tier of 2023 for Cancer Research, Hematology, and Oncology, its growing readership and open access policy enhance its visibility and impact within the scientific community. Based in Switzerland, the journal features diverse access options, reflecting the global importance of oncology research. With a focus on innovative treatments and the latest methodologies, Oncology Research and Treatment plays a crucial role in fostering collaboration and dialogue among researchers, professionals, and students alike, helping to shape the future of cancer care and management.

CA: A Cancer Journal for Clinicians is a prestigious academic journal published by Wiley, serving as a leading source of evidence-based information for those in the fields of oncology and hematology. With an impressive impact factor and ranked in the top quartile (Q1) for both specialties, this journal aims to bridge the gap between the latest research findings and clinical practice. Established in 1950, it boasts a long-standing history of delivering essential insights, guidelines, and innovative strategies to healthcare professionals worldwide, making significant contributions to the understanding and treatment of cancer. Although it does not offer open access, its published content is crucial for researchers, clinicians, and students dedicated to advancing cancer care. The journal's commitment to excellence is reflected in its elite rankings, holding the #1 position in both the Medicine – Oncology and Medicine – Hematology categories according to Scopus, positioning it in the 99th percentile of scholarly impact.

Breast Cancer is a prestigious peer-reviewed journal published by SPRINGER JAPAN KK, specializing in the multifaceted domains of oncology and medical pharmacology. With an impressive impact factor and recognized within the Q1 category in multiple areas, including Medicine (miscellaneous), Radiology, and Nuclear Medicine and Imaging, this journal serves as a fundamental resource for cutting-edge research and clinical advancements in breast cancer treatment and care. Its indexed presence in renowned databases like Scopus further affirms its significance, ranking 56th in Radiology and 60th in Pharmacology. The journal aims to bridge the gap between clinical practice and scientific research by publishing original articles, reviews, and case studies that enhance understanding and improve patient outcomes. With converged content available from 1994 to 2024, the journal is dedicated to fostering innovative research while engaging a global audience of researchers, clinicians, and students passionate about tackling breast cancer challenges.

Genetic Testing and Molecular Biomarkers, an esteemed journal published by MARY ANN LIEBERT, INC, serves as a pivotal platform for advancing the field of genetic research and its applications in medicine. Focused on the innovative intersections of genetics and biomarker discovery, this journal has consistently contributed meaningful insights since its inception in 2009, with its scope evolving through 2024. With an ISSN of 1945-0265 and an E-ISSN of 1945-0257, it offers both traditional and open access options to cater to a broad audience of researchers, professionals, and students. Despite its current classification in the Q4 and Q3 quartiles for Genetics (clinical) and Medicine (miscellaneous) respectively, the journal remains committed to publishing high-quality, peer-reviewed articles that push the boundaries of knowledge in the field. As the landscape of genomic medicine continues to expand, Genetic Testing and Molecular Biomarkers is positioned as a crucial resource for disseminating cutting-edge discoveries and fostering interdisciplinary collaboration.

Cold Spring Harbor Molecular Case Studies is a prestigious journal published by COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT, that has garnered considerable attention in the fields of Biochemistry, Genetics, and Molecular Medicine. With a focus on the intersection of molecular biology and clinical case studies, this journal serves as a key resource for researchers and practitioners seeking to explore novel insights into genetic disorders and biomedical advances. Its impact is underscored by its categorization in Q2 in various disciplines in 2023, reflecting its significance and influence within the academic community. Although currently not labeled as Open Access, Cold Spring Harbor Molecular Case Studies provides a rigorous platform for disseminating high-quality, peer-reviewed research that drives innovation and enhances understanding in these rapidly evolving fields. As a supporter of advancing scientific knowledge, this journal is essential for those dedicated to the exploration of molecular mechanisms and their clinical implications.

Cancer Causes & Control, an esteemed journal within the field of Cancer Research and Oncology, is published by SPRINGER. Since its inception in 1990, this journal has dedicated itself to exploring the complex interplay between environmental, genetic, and lifestyle factors that contribute to cancer causation and control, aiming to inform public health initiatives and improve cancer prevention strategies. With an impressive Q2 rank in both its categories, the journal serves as a vital resource for researchers, professionals, and students seeking insights into the latest findings and methodologies in cancer epidemiology. Although there is no Open Access option, researchers can access valuable articles that reflect rigorous peer review and significant contributions to the field. The journal’s commitment to advancing knowledge related to cancer risks and management makes it an essential platform for disseminating impactful research and fostering collaboration among scholars worldwide.

Chinese Journal of Cancer Research, published by Chinese Journal Cancer Research Co, is a pivotal platform for disseminating significant findings in the field of oncology. Since its inception in 1988, the journal has provided a comprehensive forum for cancer research, featuring peer-reviewed articles that cover various aspects of cancer biology, prevention, diagnosis, and treatment. Although the journal's coverage is currently discontinued in Scopus and holds an HIndex that has not been specified, it is ranked in the 65th percentile in Medicine - Oncology and the 48th percentile in Biochemistry, Genetics and Molecular Biology - Cancer Research. This reflects its commitment to maintaining quality and relevance in the rapidly evolving field of cancer research. Researchers, professionals, and students are encouraged to explore its rich archive of studies and breakthroughs to enhance their understanding and further their research. For access, the publication remains instrumental for those invested in advancing the global fight against cancer.

Lung Cancer Management, published by FUTURE MEDICINE LTD, is a premier academic journal dedicated to the evolving field of oncology and respiratory medicine. With an ISSN of 1758-1966 and an E-ISSN of 1758-1974, this journal offers a platform for the dissemination of cutting-edge research, clinical studies, and expert reviews, all focusing on the latest advances in lung cancer treatment and management. Despite being a relatively new entry since its inception in 2014 and achieving its converged years from 2020 to 2024, it has already established itself in the Q3 quartile for both oncology and pulmonary and respiratory medicine as of 2023, according to category quartiles rankings. With a Scopus ranking of #98 in the category of Pulmonary and Respiratory Medicine and #266 in Oncology, the journal reflects a commitment to quality and relevance in its content. Although it does not offer open access, it remains a crucial resource for researchers, clinicians, and students seeking to stay informed about the latest developments and practical approaches in lung cancer management. The journal is accessible from its base in the United Kingdom, at UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB, ensuring that it caters to a global audience eager to explore and contribute to this vital field of medicine.